Key facts
- Summit Therapeutics said the FDA found ivonescimab did not establish substantial evidence of effectiveness.
- Summit holds exclusive rights to develop and commercialize ivonescimab globally, according to the report.
- Akeso shares are listed in Hong Kong and fell as much as 31.8% on Monday morning.
Shares in Hong Kong-listed Akeso fell as much as 31.8% on Monday, November 16, 2026, after the US Food and Drug Administration rejected its application for the cancer drug ivonescimab.
US firm Summit Therapeutics, which holds the exclusive rights to develop and commercialize the drug globally, said the FDA found ivonescimab did not establish "substantial evidence of effectiveness." The report described ivonescimab as one of the most closely watched innovative drugs to emerge from China.
The rejection raised investor worries over Akeso's near-term commercial outlook, according to the report.
